Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5155604 | 0.85 | CA12 (0.49) | CA2CA12CA1CA4CA9 | |
| SCHEMBL8865248 | 0.83 | IDO1 (0.39) | CA2CA12CA1CA4CA9 | |
| SCHEMBL13242640 | 0.82 | SENP1 (0.46) | CA2CA12CA1CA4CA9 | |
| SCHEMBL13242629 | 0.82 | CA12 (0.54) | CA2CA12CA1CA4CA9 | |
| SCHEMBL23091915 | 0.81 | IDO1 (0.66) | CA2CA12CA1CA9IDO1 | |
| SCHEMBL5148849 | 0.81 | CA12 (0.45) | CA2CA12CA1CA4CA9 | |
| SCHEMBL5148856 | 0.81 | AGXT (0.48) | CA2CA12CA1CA4CA9 | |
| SCHEMBL186313 | 0.80 | CA12 (0.56) | CA2CA12CA1CA4CA9 | |
| SCHEMBL220304 | 0.80 | CA2 (0.53) | CA2CA12CA1CA4CA9 | |
| SCHEMBL28040548 | 0.80 | SNCA (0.50) | CA2CA12CA1CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629368-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2009-12-08 | — | — | US | disclosed |
| US-20090075952-A1 | NITRODERVIATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. | 2009-03-19 | — | — | US | disclosed |
| US-7465803-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080194651-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. | 2008-08-14 | — | — | US | disclosed |
| US-7378437-B2 | Use for the diabetes treatment of compounds or salts thereof, having the following general formula (I): A-(B)b0-(C)c0-NO2 wherein A contains the radical of a drug having an antiiflammatory or analgesic activity, B is a bivalen: linking | NICOX S.A. (FR) | 2008-05-27 | — | — | US | disclosed |
| EP-1339665-B1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX SA (FR) | 2007-12-19 | — | — | EP | disclosed |
| EP-1147074-B1 | SYNTHESIS METHOD OF NITROXYMETHYLPHENYL ESTERS OF ASPIRIN DERIVATIVES | NICOX SA (FR) | 2005-03-23 | — | — | EP | disclosed |
| EP-1194397-B1 | A PROCESS FOR OBTAINING (NITROXYMETHYL)PHENYL ESTERS OF SALICYLIC ACID DERIVATIVES | NICOX SA (FR) | 2004-09-22 | — | — | EP | disclosed |
| US-6696591-B1 | USING LOWER COST, CHEMICALLY STABLE, NONIRRITAING REACTANTS AND INTERMEDIATES; HALOACYLATION, ESTERIFICATION WITH HYDROXYBENZYLACOHOL AND NITRATION | NICOX S.A. (FR) | 2004-02-24 | — | — | US | disclosed |
| US-20040023890-A1 | Drugs for diabetes | NICOX S.A. (FR) | 2004-02-05 | — | — | US | disclosed |
| CN-1360566-A | Process for the preparation of (nitroxymethyl) phenyl esters of salicylic acid derivatives | NICOX SA (FR) | 2002-07-24 | — | — | CN | disclosed |
| EP-1194397-A1 | A PROCESS FOR OBTAINING (NITROXYMETHYL)PHENYL ESTERS OF SALICYLIC ACID DERIVATIVES | NICOX S.A. (FR) | 2002-04-10 | — | — | EP | disclosed |
| EP-1147074-A1 | SYNTHESIS METHOD OF NITROXYMETHYLPHENYL ESTERS OF ASPIRIN DERIVATIVES | NICOX S.A. (FR) | 2001-10-24 | — | — | EP | disclosed |
| CN-1305997-A | Diclofenac coupled derivative and its synthesizing process and inflammation relieving action | CHINESE PHARMACY UNIV (CN) | 2001-08-01 | — | — | CN | disclosed |
| US-6242432-B1 | ANTIHYPERTENSIVE ACTIVITY, ANTIHYPERSENSITIVE ACTIVITY; TREATMENT OF CARDIOVASCULAR DISEASE | NICOX S.A. (FR) | 2001-06-05 | — | — | US | disclosed |
| WO-2001004082-A1 | A PROCESS FOR OBTAINING (NITROXYMETHYL)PHENYL ESTERS OF SALICYLIC ACID DERIVATIVES | NICOX S.A. (FR) | 2001-01-18 | — | — | WO | disclosed |
| WO-2000044705-A1 | SYNTHESIS METHOD OF NITROXYMETHYLPHENYL ESTERS OF ASPIRIN DERIVATIVES | NICOX S.A. (FR) | 2000-08-03 | — | — | WO | disclosed |
| CN-1242768-A | Antithrombotic organic nitrates | NICOX SA (FR) | 2000-01-26 | — | — | CN | disclosed |
| EP-0941218-A1 | ANTITHROMBOTIC ORGANIC NITRATES | NICOX S.A. (FR) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998021193-A1 | ANTITHROMBOTIC ORGANIC NITRATES | NICOX S.A. (FR) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075952-A1 | NITRODERVIATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NR3C1, NR0B1, NOX1 | CA2 1735/4885CA12 2544/4885CA1 1912/4885 |
| US-20080194651-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NR3C1, NR2E1, CYP2E1 | CA2 1920/4885CA12 3168/4885CA1 2096/4885 |
| US-20040023890-A1 | Drugs for diabetes | SLC5A2, ADORA2B, UGT2B7 | CA2 79/4885CA12 236/4885CA1 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.